Sanofi: Sarclisa accepted for FDA priority review for the tr

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase

Related Keywords

United States , Paris , France General , France , American , Thomas Larsen , Evan Berland , Timothy Gilbert , Dietmar Berger , Nicolas Obrist , Felix Lauscher , Tarik Elgoutni , Corentine Driancourt , European Union , Drug Administration , Nasdaq , American Society Of Clinical Oncology , Global Head Of Development At Sanofi , European Hematology Association , World Health Organization , Euronext , Clinical Oncology , Annual Meeting , Priority Review , Biologics License Application , Medical Officer , Global Head , Hematology Association , Nonproprietary Naming , Biological Products Guidance , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Accessed March , Ihr Portfolio ,